¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"leukemia inhibitory factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
  • peripheral inhibitory field
    ¸»ÃʾïÁ¦¿µ¿ª
  • reticular inhibitory area
    ±×¹°Ã¼¾ïÁ¦ºÎÀ§
  • aplastic leukemia
    °ñ¼ö¹«Çü¼º¹éÇ÷º´
  • acute lymphocytic leukemia
    ±Þ¼º¸²ÇÁ±¸¹éÇ÷º´
  • acute myelocytic leukemia
    ±Þ¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute promyelocytic leukemia
    ±Þ¼ºÀü°ñ¼ö¼¼Æ÷¹éÇ÷º´, ±Þ¼ºÇ²°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute undifferentiated leukemia
    ±Þ¼º¹ÌºÐÈ­¹éÇ÷º´
  • adult T-cell leukemia/lymphoma
    ¼ºÀÎT¼¼Æ÷¹éÇ÷º´/¸²ÇÁÁ¾
  • aleukemic leukemia
    ¹«¹éÇ÷¼º¹éÇ÷º´
  • chloroma leukemia
    ³ì»öÁ¾¹éÇ÷º´
  • chronic lymphoblastic leukemia/small lymphocytic lymphoma
    ¸¸¼º¸²ÇÁ¸ð±¸¹éÇ÷º´/¼Ò¸²ÇÁ±¸¸²ÇÁÁ¾
  • chronic lymphocytic leukemia
    ¸¸¼º¸²ÇÁ±¸¹éÇ÷º´
  • chronic myelocytic leukemia
    ¸¸¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • eosinophilic leukemia
    È£»ê±¸¹éÇ÷º´
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory interneuron
    ¾ïÁ¦»çÀ̽Ű漼Æ÷
  • inhibitory synapse
    ¾ïÁ¦¿¬Á¢
  • inhibitory transmitter
    ¾ïÁ¦Àü´Þ¹°
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÈÄÀüÀ§
  • acute undifferentiated leukemia
    ±Þ¼º¹ÌºÐÈ­¹éÇ÷º´
  • aleukemic leukemia
    ¹«¹éÇ÷¼º¹éÇ÷º´
  • aplastic leukemia
    °ñ¼ö¹«Çü¼º¹éÇ÷º´
  • chloroma leukemia
    ³ì»öÁ¾¹éÇ÷º´
  • granulocytic leukemia
    (¢¡myelogenous leukemia) °ñ¼ö¹éÇ÷º´
  • hairy cell leukemia
    Åм¼Æ÷¹éÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • leukopenic leukemia
    (¢¡aleukemic leukemia) ¹«¹éÇ÷¼º¹éÇ÷º´
  • lymphatic leukemia
    (¢¡lymphoblastic leukemia) ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • lymphoblastic leukemia
    ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • lymphocytic leukemia
    (¢¡lymphoblastic leukemia) ¸²ÇÁ¸ð±¸¹éÇ÷º´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory nerve
    ¾ïÁ¦½Å°æ.
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory postsynaptic potential = IPSP
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory synapse
    ¾ïÁ¦¼º(åäð¤àõ) ½Ã³³½º.
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º.
  • inhibitory transmitter
    ¾ïÁ¦¼º Àü´Þ¹°Áú.
  • inhibitory zone
    ¾ïÁ¦¹üÀ§(åäð¤ÛôêÌ).
  • Burkitts acute lymphoblastic leukemia
    ¹öŰƮ ±Þ¼º ¸²ÇÁ¾Æ±¸¼º ¹éÇ÷º´
  • FAB =>French-american-British leukemia classification
    FAB ¹éÇ÷º´ºÐ·ù
  • French-American-British leukemia classification
    FAB ¹éÇ÷º´ºÐ·ù
  • Leukemia
    ¹éÇ÷º´(ÛÜúìÜ»)
  • T cell leukemia
    T¼¼Æ÷(¹éÇ÷º´
  • acute granulocytic leukemia
    ±Þ¼º °ú¸³±¸(¼º) ¹éÇ÷º´(¡­Î¨í£Ï¹àõÛÜúìÜ»).
  • acute granulocytic leukemia
    ±Þ¼º °ú¸³±¸(¼º) ¹éÇ÷º´(??ËöË´ËÛËÑÌ´ËÓ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inhibitory hormone
    ¾ïÁ¦(åäð¤)È£¸£¸ó.
  • inhibitory junctional potential
    ¾ïÁ¦¼º Á¢ÇÕºÎÀü¾Ð(ïÈùêݬï³äâ).
  • inhibitory nerve
    ¾ïÁ¦½Å°æ.
  • inhibitory nerve
    ¾ïÁ¦½Å°æ(åäð¤ãêÌè).
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
  • inhibitory postsynaptic potential = IPSP
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º.
  • inhibitory synapse
    ¾ïÁ¦¼º(åäð¤àõ) ½Ã³³½º.
  • inhibitory transmitter
    ¾ïÁ¦¼º Àü´Þ¹°Áú.
  • inhibitory zone
    ¾ïÁ¦¹üÀ§(åäð¤ÛôêÌ).
  • minimal inhibitory concentration
    ÃÖÀú¹ßÀ°ÀúÁö³óµµ(õÌî¸Û¡ëÀðæò­ÒØöô).
  • minimum inhibitory concentration
    ÃÖ¼Ò¹ßÀ°ÀúÁö³óµµ(õÌá³Û¡ëÀîÁò­ÒØöô).
  • minimum inhibitory concentration
    ÃÖ¼Ò¾ïÁ¦³óµµ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antianemia factor
    Ç׺óÇ÷ÀÎÀÚ(ù÷Þ¸úìì×í­)
  • antiberiberi factor
    Ç×°¢±âÀÎÀÚ(ù÷ÊÅѨì×í­)
  • antiblack-tongue factor
    Ç×Èæ¼³ÀÎÀÚ(ù÷ýÙàßì×í­)
  • antihemophilic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ(ù÷úìéÒÜ»ì×í­)
  • antihemophilic factor B
    Ç×Ç÷¿ìº´ÀÎÀÚ (ù÷úìéÒÜ»ì×í­) B
  • antihemophilic factor C
    Ç×Ç÷¿ìº´ÀÎÀÚ (ù÷úìéÒÜ»ì×í­) C
  • antineuritic factor
    Ç׽Ű漺ÀÎÀÚ(ù÷ãêÌèàõì×í­)
  • antinuclear factor
    Ç×ÇÙÀÎÀÚ(ù÷ú·ì×í­)
  • antipellagra factor
    Ç×(ù÷)Æç¶ó±×¶ó ÀÎÀÚ(ì×í­)
  • antipeptic ulcer factor
    Ç×(ù÷)±Ë¾ç(Ï÷åË) ÀÎÀÚ(ì×í­)
  • antipernicious anemia factor
    Ç×(ù÷)¾Ç¼ººóÇ÷(äÂàõÞ¸úì) ÀÎÀÚ(ì×í­)
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ(ù÷ÎÕúìÜ»ì×í­)
  • antisigma factor
    Ç×(ù÷)½Ã±×¸¶ ÀÎÀÚ(ì×í­)
  • antispecificity factor
    Çׯ¯À̼º ÀÎÀÚ(ù÷÷åì¶àõì×í­)
  • antisterility factor
    Ç׺ÒÀÓ ÀÎÀÚ(ù÷ÝÕìõì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
PF pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid...
LIFR leukemia inhibitory factor receptor
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LMIF Leucocyte migration inhibitory factor
LIF Leukaemia Inhibitory Factor
MIF Migration Inhibitory Factor
NIF Neutrophil inhibitory factor
OCIF OPG)-osteoclastogenesis-inhibitory factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chronic myelogenous leukemia
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´Àº Àå³âÃþ¿¡ ÁÖ·Î ¹ß»ýÇÏ¸ç ¹éÇ÷º´ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÑ´Ù. ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´Àº Á¶Ç÷¸ð¼¼Æ÷ ¼öÁØÀÇ ¾Ï¼º Áõ½ÄÀ¸·Î Áø¼º ÀûÇ÷±¸ Áõ°¡Áõ, Ç÷¼ÒÆÇ Áõ°¡Áõ ¹× °ñ¼ö ¼¶À¯È­Áõ°ú ÇÔ²² °ñ¼ö Áõ½Ä¼º ÁúȯÀ¸·Î ºÐ·ùµÈ´Ù. ¿°»öü 9¹ø°ú 22¹øÀÇ »óÈ£ ÀüÀ§·Î ÀÎÇÑ Çʶóµ¨ÇÇ¾Æ ¿°»öü¿Í ±× »ê¹°ÀÎ bcr-ablÀÌ 95% À̻󿡼­ ¾ç¼ºÀ¸·Î ÀÌ ÁúȯÀÇ º´Àΰú °ü°è°¡ ÀÖ´Â °ÍÀ¸·Î ÀÌÇØµÇ°í ÀÖ´Ù. ÁÖ Áõ»óÀº ºñÀå ºñ´ë·Î ÀÎÇÑ º¹ºÎ ÆØ¸¸ÀÌ Æ¯Â¡ÀûÀÌ¸ç ±×¿Ü °ú´ë»çÁõ µî ÀϹÝÀûÀÎ ¹éÇ÷º´ÀÇ Áõ»óÀÌ ÀÖ´Ù. Áø´ÜÀº Ç÷¾× ¼Ò°ß°ú °ñ¼ö ¼Ò°ß ±×¸®°í ¿°»öü ¹× ºÐÀÚ»ý¹°ÇÐ °Ë»ç¿¡ ÀÇÇÑ bcr-abl ÀÇ Áõ¸í¿¡ ÀÇÇÑ´Ù. ÀÌ ÁúȯÀÇ °æ°ú´Â ¾à 3³âÀÇ ¸¸¼º±â¸¦ Áö³ª°í Àüȯ±â¸¦ °Åó ±Þ¼º ¹éÇ÷º´À¸·Î ÀüȯµÇ¸ç À̶§´Â ÇöÀç ¾Ë·ÁÁø ¾î¶°ÇÑ Ä¡·á ¹æ¹ý¿¡µµ Àß ¹ÝÀÀÇÏÁö ¾Ê´Â´Ù. Ä¡·á´Â °ú°Å¿¡´Â busulfan À̶ó´Â Ç×¾ÏÁ¦°¡, ±Ù·¡¿¡´Â hydrea°¡ ÁÖ·Î »ç¿ëµÇ°í ÀÖÀ¸³ª À̵éÀº ±Þ¼º ¹éÇ÷º´À¸·ÎÀÇ ÀüȯÀ» ¸·Áö ¸øÇÏ¸ç ¹éÇ÷±¸ÀÇ Á¶Àý¿¡¸¸ µµ¿òÀÌ µÉ »Ó Çʶóµ¨ÇÇ¾Æ ¿°»öü°¡ ÀÖ´Â ¾Ï¼¼Æ÷¸¦ Á¦°ÅÇÏÁö´Â ¸øÇÑ´Ù. ±Ù·¡¿¡´Â homoharringtonine µîÀÇ ¾àÁ¦°¡ ¿¬±¸µÇ°í ÀÖ´Ù. 1990³â´ë ¿¡ µîÀåÇÑ ¾ËÆÄÀÎÅÍÆä·Ð ¿ä¹ýÀº ¾à 80%¿¡¼­ Ç÷¾× ¼Ò°ßÀÌ Á¤»óÈ­µÇ°í 20-30%¿¡¼­ Çʶóµ¨ÇÇ¾Æ ¿°»öü°¡ ¼Ò½ÇµÇ´Â µî ¿ì¼öÇÑ ¼ºÀûÀ» º¸À̰í ÀÖÀ¸³ª ±Þ¼º ¹éÇ÷º´À¸·ÎÀÇ ÀüȯÀ» ¸·Áö´Â ¸øÇÏ¸ç ¸¸¼º±â¸¦ ¾à 5³â Á¤µµ·Î ¿¬Àå½ÃŲ´Ù. ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´À» ¿ÏÄ¡½Ãų ¼ö ÀÖ´Â À¯ÀÏÇÑ Ä¡·á ¹æ¹ýÀº µ¿Á¾ °ñ¼ö À̽ÄÀ¸·Î 55¼¼±îÁö ½ÃÇàÀÌ µÈ´Ù. °ñ¼ö ÀÌ½Ä ÈÄ Àå±â ¹«º´ »ýÁ¸À²Àº ¾à 60-70%ÀÌ¸ç Æ¯È÷ Áø´ÜµÈ ÈÄ 1³â À̳»¿¡ ½ÃÇàÇÏ´Â °ÍÀÌ ±Ç°íµÈ´Ù.
  • chronic myelomonocytic leukemia
    ¸¸¼º °ñ¼ö¼º ´Ü±¸ ¹éÇ÷º´
  • hairy cell leukemia
    À¯¸ð»ó ¼¼Æ÷¼º ¹éÇ÷º´
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • lymphatic leukemia
    Àӯļº ¹éÇ÷º´
  • monomyelogenous leukemia
    ´Ü±¸ °ñ¼ö¼º ¹éÇ÷º´
  • radiation leukemia
    ¹æ»ç¼± ¹éÇ÷º´
  • subleukemic leukemia
    ¾Æ¹éÇ÷¼º ¹éÇ÷º´
  • T-cell leukemia-lymphoma virus
    T Çü ¼¼Æ÷ ¹éÇ÷º´-ÀÓÆÄÁ¾ ¹ÙÀÌ·¯½º
  • central inhibitory connection
    ÁßÃß ¾ïÁ¦ ¿¬°á
  • descending inhibitory system
    ÇÏÇà ¾ïÁ¦°è
  • inhibitory
    ¾ïÁ¦¼º
    °úÁ¤À» ¾ïÁ¦ ¶Ç´Â ÀúÁöÇÏ´Â. ºÎºÐÀûÀ¸·Î ¶Ç´Â ¿ÏÀüÈ÷ Á¤Ã¼, Á¤Áö½ÃŰ´Â.
  • inhibitory afferent input
    ¾ïÁ¦¼º ±¸½É¼º ÀÔ·Â
  • inhibitory contribution
    ¾ïÁ¦¼º ºÐÆ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
leukocyte migration-inhibitory factors Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat).
(12 Dec 1998)
accelerator factor <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
acetate replacement factor <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms.
(18 Nov 1997)
adrenal weight factor A postulated substance of adenohypophysial origin responsible for maintenance of the weight of the adrenal cortex.
(05 Mar 2000)
adrenocorticotropic releasing factor Hormone produced by hypothalamus that causes pituitary to secrete adrenocorticotropic hormone.
(05 Mar 2000)
a-factor <molecular biology> A protein which is found in the bacterial genus Streptomyces that helps start the production of streptomycin and the process of morphological differentiation.
It is used in biotechnology to induce these functions in mutant strains of Streptomyces that cannot produce it themselves.
(09 Feb 1998)
angiogenesis factor Substance causing proliferation of new blood vessels. It is found in tissues with high metabolic requirements, such as the retina, and in certain cancers. The factor is also released by hypoxic macrophages at the edges or outer surfaces of wounds and initiates revascularization in wound healing.
(12 Dec 1998)
animal protein factor <biochemistry> Member of the water soluble B vitamin group, important in the proper function of the nervous system and important in proper carbohydrate, protein and fat metabolism.
(27 Sep 1997)
antialopecia factor A member of the vitamin B complex necessary for growth of yeast and of mice, absence from the diet causes hair loss and dermatitis in mice.
(27 Sep 1997)
antianaemic factor <biochemistry> Member of the water soluble B vitamin group, important in the proper function of the nervous system and important in proper carbohydrate, protein and fat metabolism.
(27 Sep 1997)
antiberiberi factor Synonym: thiamin.
(05 Mar 2000)
anti-black-tongue factor A precursor of NAD, that is a product of the oxidation of nicotine.
(18 Nov 1997)
anticomplementary factor A factor that interferes with the action or function of complement.
(05 Mar 2000)
antidermatitis factor <chemical> Chemical name: beta-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (R)-
(12 Dec 1998)
antihemophilic factor A A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • factor cost
    ¿äÀÎ(¿ä¼­)ºñ¿ë
  • intrinsic factor
    (»ýÈ­)³»À缺ÀÎÀÚ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á